

Supplementary Table 8

Progression-free survival (A) and overall survival (B) by dexmedetomidine use in awake craniotomy group

(A) Progression free survival (p<0.312)

	Time Period	Progression	Median survival (95% CI)	Survivor Function (95% CI)
No (n = 142)	Overall	132 (92.96%)	0.54 (0.42-0.74)	
	1 year	97 (68.31%)		0.31 (0.24-0.39)
	2 year	21 (14.79%)		0.16 (0.10-0.22)
	5 year	12 (8.45%)		0.06 (0.03 -0.11)
	10 year	2 (1.41%)		--
Yes (n = 45)	Overall	43 (95.56%)	0.54 (0.45-0.76)	
	1 year	33 (73.33%)		0.25 (0.14-0.39)
	2 year	6 (13.33%)		0.11 (0.04-0.23)
	5 year	4 (8.89%)		--
	10 year	0		--

(B) Overall survival (p<0.900)

	Time Period	Deaths	Median survival (95% CI)	Survivor Function (95% CI)
No (n = 142)	Overall	91 (64.08%)	1.68 (1.26-2.33)	
	1 year	47 (33.10%)		0.65 (0.56-0.72)
	2 year	23 (16.20%)		0.46 (0.37-0.54)
	5 year	18 (12.68%)		0.23 (0.15-0.33)
	10 year	3 (2.11%)		--
Yes (n = 45)	Overall	23 51.11%)	1.80 (1.23-3.28)	
	1 year	10 (22.22%)		0.75 (0.59-0.86)
	2 year	9 (20.00%)		0.46 (0.28-0.62)
	5 year	4 (8.89%)		--
	10 year	0		--

CI, confidence interval